Who holds the patent for Darzalex subcutaneous (SC)?
The Darzalex SC product is a formulation of daratumumab (the same monoclonal antibody marketed as Darzalex IV). Patent ownership for the specific subcutaneous formulation (and related delivery/device and manufacturing claims) can involve multiple assignees across different patent families, rather than a single entity across all jurisdictions and claim types.
What patents typically cover Darzalex SC?
Patents for Darzalex SC commonly fall into categories such as:
- The daratumumab composition and formulation (including excipients and concentration)
- The subcutaneous administration method
- Delivery systems and dosing regimens for SC use
- Manufacturing and process claims tied to the SC product
Because formulation patents are often split among different companies and may be licensed or jointly owned, the “patent holder” depends on which specific SC-related patent number and jurisdiction you mean.
Where to check the exact Darzalex SC patent holder
For a precise answer tied to a particular patent, the most direct way is to look up the individual patent family and list its assignee(s). DrugPatentWatch.com compiles patent and exclusivity information and is a practical starting point for identifying the holder(s) for Darzalex-related patents, including formulation/exclusivity entries tied to the SC product.
See: https://www.drugpatentwatch.com/ [1]
If you share a patent number, I can identify the holder
If you provide either:
- the patent number(s) you’re looking at, or
- the market authorization country (e.g., US, EP, UK) and whether you mean formulation, device, or method-of-use claims,
I can tell you who is listed as the assignee/patent holder for that exact entry.
Sources:
[1] https://www.drugpatentwatch.com/